Published by
@ShahidNShah
@ShahidNShah
March 18 to March 20, 2024
Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States
The highly anticipated 7th Antigen-Specific Immune Tolerance Drug Development Summit, taking place from Mon, 18 Mar 2024 to Wed, 20 Mar 2024, is a premier industry forum dedicated to showcasing the latest advancements in tolerogenic therapies. This pivotal event encompasses discoveries in preclinical and clinical development, emphasizing biomarkers and proof-of-concept studies. Immune tolerance strategies hold immense potential, not solely for treating but potentially curing autoimmune diseases. These approaches, such as those being pursued in Diamyd's phase III trial for type I diabetes, COUR, Anokion, Imcyse, Takeda, and Selecta's phase II trials, signify a promising shift away from standard immunosuppression therapies, heralding a transformative era in biopharma's quest to deliver efficacious antigen-specific treatments to patients in need.
Read on as-immunetolerance.com
Continue reading at as-immunetolerance.com
March 18 to March 20, 2024
Village Hotel Bugis 390 Victoria St, Singapore 188061
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 20, 2024 at 12:59pm